Bulgaria

BMI View: While the value of the fine administered to Sofia-based drugmaker Adipharm for imitating one of Bayer's product is quite small, the decision by Bulgaria's Commission on the... 2011-11-04

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: While certain aspects of Bulgaria's law on medicinal products in human medicine have negative implications for drugmakers operating in the country, we maintain the view that... 2011-08-08

BMI View: Despite the prospect of lower prices as a result of amendments to the drug reference pricing system, Bulgaria's pharmaceutical market looks set for high single-figure growth... 2011-05-09

BMI View: Sopharma's successful transition from a domestically-focused drugmaker to a substantial exporter of pharmaceuticals to Eastern and South Eastern Europe denotes its potential... 2011-04-19

BMI View: While the reintroduction of medicines previously available in Bulgaria offers drugmakers a small opportunity to access this dynamic growth market, BMI highlights that financial... 2011-03-15